Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ivonescimab Beats Durvalumab in Phase III Biliary Tract Cancer Trial

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

Ivonescimab plus chemotherapy significantly outperformed durvalumab plus chemotherapy in overall survival for first-line advanced biliary tract cancer in the Phase III HARMONi-GI1 trial, directly challenging the current standard of care.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a new approval horizon with ivonescimab's positive survival results challenging the first-line biliary cancer standard. Prepare regulatory filings and market strategies around a potentially superior treatment that could reset comparators.

◆ Coverage

1 source · 27 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiliary-tract-cancerphase-3-clinical-trialimmunotherapyoncologyregulatory-pathway